Immunotherapy Rechallenge in NSCLC Yields Overall Survival Boost
CHICAGO — Randomized data suggest that an anti-angiogenic agent can kick-start immunotherapy’s antitumor activity in non-small cell lung cancer (NSCLC) patients whose disease has already progressed after chemotherapy and a checkpoint inhibitor. In the phase II study, median overall survival improved by nearly 3 months with ramucirumab (Cyramza) plus pembrolizumab (Keytruda) versus standard-of-care options (14.5 […]